Sat. Jul 20th, 2024

Aker BioMarine has been granted a patent for its PL+EPA/DHA delivery technology

By Vaseline May30,2024

Aker BioMarine has received its first patent grant for its PL+ DHA/EPA delivery technology platform, marking a significant milestone for the company’s innovation pipeline.

Launched in late 2022, Aker BioMarine’s PL+ technology uses natural marine phospholipids (PLs) to maximize the absorption of other ingredients.

It enables dual solubility in water and in fats and acts as an emulsifier and absorption booster to improve the absorption of supplements by up to 25x.

Krill and fish phospholipids for better health

This new patent application protects the PL+ EPA/DHA formulation, which is based on a mixture of krill phospholipids and EPA and DHA from processed fish oil (processed into ethyl esters).

It shows that the combination of krill phospholipids and added ethyl esters (or triglycerides) results in improved emulsions, which are believed to be essential to improve the absorption of EPA and DHA in the stomach.

The patent claims and protects lipid formulations for use in therapy to improve the absorption of fish oil derivatives, with the following key features:

  • 17-75 percent by weight of total phospholipids, i.e. 17 g to 75 g of phospholipids per 100 g of the composition
  • 16-50% by weight DHA and/or EPA in the form of ethyl esters where the formulation forms an emulsion with a preferable droplet size in the stomach

“In today’s market, we know consumers are looking for personalization and combination products to achieve important health benefits. And at a time when our industry is facing fish oil supply and demand challenges, PL+ allows us to reduce fish oil integration into a formula, while increasing bioavailability, improving the consumer experience and driving new innovations in the category possible.” say Simon Seward, CEO of Human Health Ingredients.

Related Post